Nordea to release half-year results on July 17

Frank Vang-Jensen President and Group Chief Executive Officer Nordea Bank
Frank Vang-Jensen President and Group Chief Executive Officer - Nordea Bank
0Comments

Nordea is set to release its half-year results for 2025 on July 17. The report will be available at approximately 07:30 EET (06:30 CET) on that day.

A webcast presentation is scheduled for 11:00 EET (10:00 CET), where Frank Vang-Jensen, President and Group CEO, will present the results. This will be followed by a Q&A audio session with investors and analysts. Joining him for the session will be Ian Smith, Group CFO, and Ilkka Ottoila, Head of Investor Relations.

Participants can join the live webcast through a provided link. During the Q&A session, questions can be directed to management via phone. To participate in the teleconference, registration is required through a specific link. Upon registering, participants will receive phone numbers along with user and conference IDs needed to access the conference. To ask questions during the call, participants should press #5 on their telephone keypad.

An indexed on-demand replay of the call will be made available afterward.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.